The winners of Fast Company’s 2022 World Changing Ideas Awards were recently announced, honoring clean technology, innovative corporate initiatives, brave new designs for cities and buildings, and other creative works that are supporting the growth of positive social innovation, tackling social inequality, climate change, and public health crises.

Genialis’ ResponderID, an AI/ML-enabled platform for clinical biomarker discovery, was received honorable mention in the AI & Data category. 

Precision medicine is the notion that each patient’s disease is unique and should be treated accordingly. This requires us to decipher that uniqueness using diagnostic algorithms (biomarkers) and then intervene with the appropriate therapy. ResponderID™ is an AI/ML-enabled platform specifically for modeling complex disease biology. ResponderID outputs predictive biomarkers ready for use in patients in the clinic. Upon validation in patients that the models have learned the relevant biology, these models are tuned for novel drug discovery. Thus, via real patients in the real world, ResponderID links the diagnostic application of machine learning with the invention of new therapies. ResponderID optimally positions today’s drugs for today’s patients while minimizing clinical trial failure and helps find the most promising therapeutic opportunities for terminally ill patients for whom no good treatments exist. 

“ResponderID is already used to improve the efficiency, effectiveness, and success rate of drug development and discovery. Through numerous collaborations, ResponderID is building computational models to help treat cancers like gastric, colorectal, ovarian, lung, melanoma, acute myeloid leukemia, and others,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “We are honored by this recognition from Fast Company and are excited to put in the hard work needed to use our world changing idea to actually change the world through better therapies for all diseases with an unmet need.”

Share this story, choose your platform!